Background Image



Mundipharma is committed to developing innovative therapeutic solutions that will make a true impact on the daily lives of millions of sufferers of respiratory diseases across the world.

FlutiformTM Formeterol Fumerate and Fluticasone Proprionate

The product range includes:

FlutiformTM (fluticasone/formoterol) combines fluticasone an inhaled corticosteroid with formoterol fumarate, a long-acting β2 agonist in a single HDI (High Deposition Inhaler) device, which delivers an aerosol of fine particles at a consistent dose.

TM Flutiform is a trademark of Mundipharma AG in UAE and is either registered trademark or trademark in other countries.

Please refer to individual countries for full local prescribing information and indications as approved by relative health authorities

* Not all products or indications are available in all countries. Products are currently under registrations across Middle East, Turkey and Africa Region and subject to approval according to local laws and regulations.

Please refer to your local representative office and the locally approved prescribing information for more details on the product and indications. Furthermore, Mundipharma Middle East FZLLC provides the information for readers from many countries in the ME region as of this date and does not undertake any obligation to update any forward-looking statements contained in this newsletter as a result of new information, future events or otherwise.

WordPress Video Lightbox Plugin